DOCSLIB.ORG

7.5 G/50Ml Injection 6545 4874

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
7.5 G/50Ml Injection 6545 4874 Source Quantity (Incomparable Units) Dec-18 Jan-19 Feb-19 Mar-19 POTASSIUM CHLORIDE STRONG (50mL) 7.5 g/50mL Injection 6545 4874 6099 5565 CALCIUM GLUCONATE (50mL) 10 % Solution for Injection 5942 3353 4895 3807 SODIUM ACETATE (50mL) 30 % Injection 1052 787 539 675 SPIRONOLACTONE [UNLICENSED] 50 mg/5mL Oral Suspension Sugar Free 886 1148 833 1208 mercaptoPURINE [UNLICENSED] 10 mg Tablets 552 669 524 497 POTASSIUM CHLORIDE in 50mL WATER FOR INJECTION [UNLICENSED] 50 mmol Intravenous Infusion ISONIAZID [UNLICENSED] 50 mg/5mL Oral Solution Sugar Free 506 10 1500 2 POTASSIUM CHLORIDE 50mmol/50ml [UNLICENSED] Pre-filled injection syringe 450 520 350 600 FLECAINIDE ACETATE [UNLICENSED] 25 mg/5mL Oral Solution 304 11 629 hydrALAZINE [UNLICENSED] 10 mg Tablets 191 361 62 64 GLUCOSE, SODIUM CITRATE AND SODIUM CHLORIDE 20g/2.6g/3.5g Oral Powder 30 65 143 41 TRANEXAMIC ACID 5% Mouthwash 3 703 608 302 L-CITRULLINE [UNLICENSED] 500 mg Sachets 1 CLONIDINE [UNLICENSED] 50 micrograms/5mL Oral Solution 110 55 153 16 CHLORAL HYDRATE [UNLICENSED] 500 mg/5mL Syrup 21 158 9 22 SODIUM PHOSPHATE 1mmol Na, 0.5mmol Phos in 1mL 17.9 % Oral Solution 88 63 56 141 SODIUM HYALURONATE [HEALON PRO] 10 mg/1mL Soln for Inject PF Syringes FLUOROURACIL 200 mg/8mL Pre-filled injection syringe 88 84 83 78 ORA SWEET Syrup EPIRUBICIN 60 mg/30mL Pre-filled injection syringe 86 72 66 70 SPIRONOLACTONE [UNLICENSED] 10 mg/5mL Oral Suspension Sugar Free 134 62 2 255 Melatonin_Oral Soln 5mg/5ml 279 279 SODIUM CHLORIDE (30%) (5.1mmol/mL) [UNLICENSED] 1.46 g/5mL Oral Solution 44 41 52 43 EPIRUBICIN 50 mg/25mL Pre-filled injection syringe 79 63 59 51 CYCLOPHOSPHAMIDE 500 mg/25mL Pre-filled injection syringe 63 65 56 57 METOLAZONE [UNLICENSED] 5 mg Tablets 57 80 44 36 FLUOROURACIL 500 mg/20mL Pre-filled injection syringe 58 60 60 62 CYCLOPHOSPHAMIDE 200 mg/10mL Pre-filled injection syringe 64 61 52 52 BETAINE [UNLICENSED] 2.5 g/5mL Oral Solution 33 112 19 10 SODIUM BENZOATE [UNLICENSED] 500 mg/5mL Oral Solution 1 48 134 CHLOROTHIAZIDE [UNLICENSED] 250 mg/5mL Oral Suspension Sugar Free 10 -4 16 15 CYCLOPHOSPHAMIDE 600 mg/30mL Pre-filled injection syringe 52 55 43 45 SULTIAME [UNLICENSED] 50 mg Tablets 7 1 18 VANCOMYCIN [UNLICENSED] 10 mg/1mL Intrathecal Injection 70 24 60 14 PRISTINAMYCIN [UNLICENSED] 500 mg Tablets 39 87 COCAINE ENT [UNLICENSED] 5 % Spray 24 35 31 37 POLIHEXANIDE [UNLICENSED] 0.06 % Eye Drops Preservative Free 24 48 22 49 prednisoLONE [UNLICENSED] 1 % Eye Drops Preservative Free 33 17 34 26 TACROLIMUS [TACROSE] [UNLICENSED] 2.5 mg/5mL Oral Suspension 21 33 36 39 VINCRISTINE 2 mg/50mL SODIUM CHLORIDE 0.9% IV Infusion Pre-filled Bag 30 35 30 35 cefUROXime [SPECIALS LICENSED] 5 % Eye Drops 35 29 30 39 ITRACONAZOLE 50 mg/5mL Oral Solution 65 101 56 86 FLUOROURACIL 600 mg/24mL Pre-filled injection syringe 45 37 38 32 MEPACRINE HYDROCHLORIDE [UNLICENSED] 100 mg Tablets PHENOBARBITAL [ROSEMONT] [UNLICENSED] 50 mg/5mL Oral Solution Sugar Free 5 303 2 LIDOCAINE AND ADRENALINE IN TETRACAINE 4%/0.1% [UNLICENSED] Gel 50 48 23 MELATONIN [UNLICENSED] 5 mg in 5mL Liquid 15 29 9 20 PROBENECID [UNLICENSED] 500 mg Tablets DOXORUBICIN 50 mg/25mL Pre-filled injection syringe 30 40 25 18 BACLOFEN 15 mg in 5mL Intrathecal Injection 16 28 20 20 POT CHLORIDE (20mmol/L) + NaCl + GLUCOSE (0.15%/0.45%/ 2.5%) Infusion 20 24 21 33 AZATHIOPRINE [UNLICENSED] 50 mg/5mL Oral Suspension 8 34 20 22 GEMCITABINE 1900 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 28 28 32 15 Melatonin_Oral Soln 5mg/5ml S/F SODIUM BENZOATE [UNLICENSED] 500 mg Tablets 27 38 7 DOXORUBICIN 20 mg/10mL Pre-filled injection syringe 13 36 17 16 SODIUM HYALURONATE [HEALON GV PRO] 18 mg/1mL Injection 8-METHOXYPSORALEN [UNLICENSED] 10 mg Tablets 2 32 ACETIC ACID (NON STERILE) [UNLICENSED] 3 % Solution 22 18 18 17 CARBOPLATIN 500 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 18 20 22 23 DEXTROMETHORPHAN [UNLICENSED] 30 mg/5mL Liquid 20 24 GEMCITABINE 1710 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 20 22 17 16 MIDAZOLAM [EPISTATUS] [UNLICENSED] 10 mg/1mL Buccal Liquid 25 8 11 12 INSULIN [HUMULIN R KWIKPEN] (HIGH STRENGTH) [UNLICENSED] 500 units/1mL Soln for Inject PF Disp Device 18 41 31 GEMCITABINE 1520 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 25 29 21 20 CARBOPLATIN 560 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 13 16 18 27 GLUCOSE AND SODIUM CHLORIDE 10% in 0.45% [UNLICENSED] Infusion 1 36 1 13 HYDROXOCOBALAMIN [UNLICENSED] 10 mg/2mL Intramuscular Injection 20 15 14 CHOLESTEROL [UNLICENSED] 150 mg/1mL Oral Suspension 35 11 26 CICLOSPORIN [UNLICENSED] 0.2 % Eye Ointment 17 23 4 30 CARBOPLATIN 400 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 28 24 16 18 CO-CARELDOPA (CARBIDOPA/LEVODOPA) 1.25/5mg/1mL (SPECIAL) Oral Suspension 8 11 9 21 DOCETAXEL 132 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 5 15 18 21 POTASSIUM CANRENOATE (Kalii Canrenoas) [UNLICENSED] 200 mg Intravenous Injection 8 9 10 5 8-METHOXYPSORALEN [UNLICENSED] 1.2 % Bath Additive 2 34 59 CARBOPLATIN 630 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 10 13 13 15 PRAZIQUANTEL [UNLICENSED] 500 mg Tablets 79 90 POT CHLORIDE (40mmol/L) + NaCl + GLUCOSE (0.3%/0.45%/10%) 500 mL Infusion 12 12 52 PARALDEHYDE AND OLIVE OIL [UNLICENSED] 50/50 Enema Solution 18 11 16 9 DILTIAZEM [UNLICENSED] 2 % Cream 15 18 9 11 BORTEZOMIB 2.25 mg/0.9mL Prefilled SC injection syringe 1 9 6 4 CARBOPLATIN 700 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 17 13 10 16 DOCETAXEL 148 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 5 17 15 14 GEMCITABINE 2128 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 18 18 13 14 GEMCITABINE 1368 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 16 22 20 19 TRANEXAMIC ACID [UNLICENSED] 500 mg/5mL Oral Solution 10 3 10 19 SODIUM CITRATE 441.17 mg/5mL Oral Solution 7 20 8 8 CHLORAL HYDRATE [UNLICENSED] 250 mg Suppositories 13 5 21 10 DOCETAXEL 120 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 7 19 11 11 PARACETAMOL [UNLICENSED] 15 mg Suppositories 13 7 12 8 ONDANSETRON 4 mg/5mL Oral Solution 28 30 4 L-ARGININE [UNLICENSED] 100 mg/1mL Oral Solution 5 12 13 7 NADOLOL (SPECIALS LICENSED) 4 mg/1mL Suspension 4 2 5 6 BORTEZOMIB 2.5 mg/1mL Prefilled SC injection syringe 2 17 16 5 CARBOPLATIN 450 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 10 8 9 12 OXALIPLATIN 250 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 8 11 11 9 DOXORUBICIN 60 mg/30mL Pre-filled injection syringe 17 10 12 8 CARBOPLATIN 790 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 7 12 12 10 MELATONIN [UNLICENSED] 1 mg/1mL Oral Solution Sugar Free 6 5 13 15 Diltiazem HCl_Crm 2% 30 30 INDOMETACIN [UNLICENSED] 25 mg/5mL Oral Suspension 8 14 6 7 MEXILETINE [UNLICENSED] 10 mg/1mL Suspension 7 14 7 11 CALCIUM CARBONATE [UNLICENSED] 600 mg/5mL Oral Suspension 12 12 7 11 SODIUM BICARBONATE [UNLICENSED] 4.2 % Injection 5 3 4 ISOPRENALINE SULFATE [UNLICENSED] 5 mg/5mL Injection 12 7 7 10 CHLORAL HYDRATE [UNLICENSED] 500 mg Suppositories 12 10 21 10 THIOPENTAL SODIUM 500 mg in 20mL Intravenous Injection 10 10 20 40 PROCAINE BENZYLPENICILLIN G [UNLICENSED] 1.2 million unit Injection 20 BEVACIZUMAB [UNLICENSED] 1.25 mg/0.05mL Soln for Inject PF Syringes 15 15 15 14 DOXORUBICIN 5 mg/2.5mL Pre-filled injection syringe 9 11 15 12 Hyoscine Butylbrom_Oral Soln 10mg/5ml OXANDROLONE [UNLICENSED] 2.5 mg Tablets 22 SODIUM BICARBONATE [UNLICENSED] 5mL 4.2 % Injection INTERFERON ALFA-2B [UNLICENSED] 1000000 units/1mL Eye Drops Preservative Free 10 13 14 9 CARBOPLATIN 360 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 7 12 10 8 Carvedilol_Oral Susp 5mg/5ml DOCETAXEL 108 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 3 8 6 13 MANNITOL [UNLICENSED] 2.5 % Oral Solution 7 9 4 5 EPIRUBICIN 20 mg/10mL Pre-filled injection syringe 11 10 11 9 BETAINE [UNLICENSED] 500 mg Tablets 20 16 POTASSIUM PHOSPHATE [UNLICENSED] 17.42 % w/v Oral Solution 12 21 20 BORTEZOMIB 2 mg/0.8mL Prefilled SC injection syringe 5 9 7 14 mercaptAMINE PRESERVATIVE FREE [UNLICENSED] 0.55 % Eye Drops 2 8 L-ORNITHINE Oral Powder 14 20 Ranitidine HCl_Liq Spec 75mg/5ml 38 PERAMPANEL [UNLICENSED] 4 mg/5mL Oral Suspension 4 11 8 6 OXALIPLATIN 280 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 9 8 8 5 MANNITOL 2.5% S10 Oral Solution 2 18 6 12 PARACETAMOL MINI [UNLICENSED] 30 mg Suppositories 6 4 2 11 ADENOSINE [UNLICENSED] 120 mg/120mL Infusion 7 5 3 5 PAPAVERINE [UNLICENSED] 40 mg/2mL Solution for Injection 8 7 5 11 CHORIONIC GONADOTROPHIN [UNLICENSED] [GONASI] 2000 unit Pwd + Solv for Soln for Inj 2 10 7 6 Omeprazole_Oral Susp 5mg/5ml 84 VANCOMYCIN [UNLICENSED] 1.4 % Eye Drops Preservative Free 2 0 82 Flunarizine Dihydroch_Cap 5mg OXALIPLATIN 225 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 4 7 5 7 AJMALINE [UNLICENSED] 50 mg/10mL Injection 6 15 6 3 BEVACIZUMAB [UNLICENSED] 1.25 mg/0.05mL Intravitreal Injection FLUORESCEIN (5ml) [UNLICENSED] 20 % w/v Injection 2 3 5 GEMCITABINE 1254 mg/250mL SODIUM CHLORIDE 0.9% IV Infusion Pre- filled Bag 4 6 10 8 HEXAMIDINE DI-ISETIONATE [UNLICENSED] 0.1 % Eye Drops 9 9 4 8 OXYBUTYNIN 5 mg/5mL Oral Solution 3 8 5 1 METHOTREXATE 10 mg/5mL Oral Solution 6 3 3 2 IODISED OIL (IODINE 480mg/mL) [LIPIODOL ULTRA FLUID] Solution for Injection 6 4 8 AMIODARONE [UNLICENSED] 50 mg/5mL Suspension 6 7 3 4 GENTAMICIN [UNLICENSED] 1.5 % Eye Drops Preservative Free 19 5 4 BORTEZOMIB 2.75 mg/1.1mL Prefilled SC injection syringe 1 6 8 7 CARBOPLATIN 330 mg/500mL GLUCOSE 5% Intravenous Infusion Pre- filled Bag 13 9 5 4
Load more

Recommended publications
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Mineralocorticoid Receptor Antagonists for Heart Failure with Reduced Ejection Fraction: Integrating Evidence Into Clinical Practice
    European Heart Journal Advance Access published August 31, 2012 European Heart Journal REVIEW doi:10.1093/eurheartj/ehs257 Novel Therapeutic Concepts Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice Faiez Zannad1*, Wendy Gattis Stough2,PatrickRossignol1, Johann Bauersachs3, John J.V. McMurray4,KarlSwedberg5,AllanD.Struthers6, Adriaan A. Voors7, Luis M. Ruilope8,GeorgeL.Bakris9, Christopher M. O’Connor10, Mihai Gheorghiade11, Downloaded from Robert J. Mentz10, Alain Cohen-Solal12,AldoP.Maggioni13, Farzin Beygui14, Gerasimos S. Filippatos15,ZiadA.Massy16, Atul Pathak17, Ileana L. Pin˜a18, Hani N. Sabbah19, Domenic A. Sica20, Luigi Tavazzi21, and Bertram Pitt22 http://eurheartj.oxfordjournals.org/ 1INSERM, Centre d’Investigation Clinique 9501 and Unite´ 961, Centre Hospitalier Universitaire, and the Department of Cardiology, Nancy University, Universite´ de Lorraine, Nancy, France; 2Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA; 3Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany; 4Western Infirmary and the British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; 5Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 6University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; 7University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; 8Hypertension
    [Show full text]
  • 6. References
    332 IARC MONOGRAPHS VOLUME 91 6. References Abramov, Y., Borik, S., Yahalom, C., Fatum, M., Avgil, G., Brzezinski, A. & Banin, E. (2004) The effect of hormone therapy on the risk for age-related maculopathy in postmenopausal women. Menopause, 11, 62–68 Adams, M.R., Register, T.C., Golden, D.L., Wagner, JD. & Williams, J.K. (1997) Medroxyproges- terone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. vasc. Biol., 17, 217–221 Adjei, A.A. & Weinshilboum, R.M. (2002) Catecholestrogen sulfation: Possible role in carcino- genesis. Biochem. biophys. Res. Commun., 292, 402–408 Adjei, A.A., Thomae, B.A., Prondzinski, J.L., Eckloff, B.W., Wieben, E.D. & Weinshilboum, R.M. (2003) Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: Gene resequencing and functional genomics. Br. J. Pharmacol., 139, 1373–1382 Ahmad, M.E., Shadab, G.G.H.A., Hoda, A. & Afzal, M. (2000) Genotoxic effects of estradiol-17β on human lymphocyte chromosomes. Mutat. Res., 466, 109–115 COMBINED ESTROGEN−PROTESTOGEN MENOPAUSAL THERAPY 333 Ahmad, M.E., Shadab, G.G.H.A., Azfer, M.A. & Afzal, M. (2001) Evaluation of genotoxic poten- tial of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro. Mutat. Res., 494, 13–20 Aitken, J.M., Hart, D.M. & Lindsay, R. (1973) Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br. med. J., 3, 515–518 Al-Azzawi, F., Wahab, M., Thompson, J., Whitehead, M. & Thompson, W. (1999) Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: A dose-ranging study. Hum. Reprod., 14, 636–641 Albert, C., Vallée, M., Beaudry, G., Belanger, A.
    [Show full text]
  • Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms
    COMBINED ESTROGEN−PROGESTOGEN CONTRACEPTIVES 143 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion in humans The metabolism and disposition of various formulations of oral contraceptives used in humans differ. After entering the small intestine, estrogenic and progestogenic compounds in combined oral contraceptives undergo metabolism by bacterial enzymes and enzymes in the intestinal mucosa to varying extents. The mixture of metabolized and unmetabolized compounds then undergoes intestinal absorption, and thus enters the portal vein blood, which perfuses the liver. In the liver, the compounds can be metabolized extensively, which leads to variations in the amount of active drug. A fraction of the absorbed dose of ethinyl- estradiol and some progestogens is also excreted in the bile during its first transit through the liver. Although some of these compounds are partially reabsorbed via the enterohepatic circulation, a fraction may also be excreted in this ‘first pass’, which reduces overall bio- availability. Since steroids penetrate normal skin easily, various systems have also been developed that deliver estrogens and progestogens parenterally, e.g. transdermal patches, nasal sprays, subcutaneous implants, vaginal rings and intrauterine devices (Fanchin et al., 1997; Dezarnaulds & Fraser, 2002; Meirik et al., 2003; Sarkar, 2003; Wildemeersch et al., 2003; Sturdee et al., 2004). These different modes of administration have been described previously (IARC, 1999). In general, all parenteral routes avoid loss of the drug by hepatic first-pass metabolism and minimally affect hepatic protein metabolism. The absorption rates of orally administered estrogens and progestogens are usually rapid; peak serum values are observed between 0.5 and 4 h after intake.
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Answered On:13.12.2000 Marketing of Drugs Kanti Singh;Raghuvansh Prasad Singh
    GOVERNMENT OF INDIA HEALTH AND FAMILY WELFARE LOK SABHA STARRED QUESTION NO:344 ANSWERED ON:13.12.2000 MARKETING OF DRUGS KANTI SINGH;RAGHUVANSH PRASAD SINGH Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state: (a) whether the Government are aware that various drugs and formulations banned in USA and other foreign countries are still being marketed in the country; (b) if so, the details thereof; (c) whether the Government have examined this issue in consultation with various laboratories and other experts of the All India Institute of Medical Sciences; and (d) if so, the details of such banned drugs allowed to be marketed in the country? Answer THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI A. RAJA) (a) to (d): A statement is laid on the Table of the Lok Sabha. STATEMENT REFERRED TO IN REPLY TO LOK SABHA STARRED QUESTION NO. 344 FOR 13.12.2000 Certain drugs and formulations banned in some countries at times continue to be marketed in other countries because the decision to do so is normally based on risk assessment process which is influenced by a number of factors such as the disease pattern in a country, the varying reactions of certain ethnic groups in a given population to the drug and the availability of safer substitutes as well as the cost factor involved in the treatment of a particular disease. There is also the overall awareness that administration of any drug is not absolutely free from side effects or adverse reactions in a statistically insignificant minority of the population.
    [Show full text]
  • Dosage and Administration
    HGDS"'FG ·-···--··-· ..---- ·---·' .. e ·--­··---····~·----- 133 Molesworth Street PO Box5013 Wellington 6140 New Zealand T +64 4 496 2000 1 February 2019 Response to your request for official information I refer to your request of 4 January 2019 to the Ministry of Health (the Ministry), under the Official Information Act 1982 (the Act), for. "I wish to request the following information regarding (the now lapsed) Aldactone, film coated tablets, spironolactone 25 mg and 100mg (TTS0-1764, 1764a): • Please provide a copy of the most recent datasheet (approved in a CMN or notified ina SACN). • Please provide a copy of the most recent primary and secondary labelling (approved in a CMN or notified in a SACN). • Please advise if the approved NZ labelling included an ARTG number." Information held by the Ministry relating to your request is itemised below, with copies of documents attached. Attachment Details and decision number - Data sheet for Aldactone 25 mg and Aldactone 100 mg. 1 Information released in full. Copy of the primary and secondary labelling for Aldactone 25 mg and 2 Aldactone 100 mg. Information released in full. In response to part three of your request, the Ministry confirms that the approved secondary labelling for Aldactone 25 mg and Aldactone 100 mg in New Zealand contained Australian Register of Therapeutic Goods (ARTG) numbers: AUST R 68953 (Aldactone 25 mg) and AUST R 68954 (Aldactone 100 mg). I trust this information fulfils your request. Please note this response (with your personal details removed) may be published on the Ministry of Health website. Yours si r;,c;:arely ~ r,,..~-~/___/ / /..
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Stress-Induced Alterations of Social Behavior Are Reversible by Antagonism of Steroid Hormones in C57/BL6 Mice
    Naunyn-Schmiedeberg's Archives of Pharmacology https://doi.org/10.1007/s00210-020-01970-7 ORIGINAL ARTICLE Stress-induced alterations of social behavior are reversible by antagonism of steroid hormones in C57/BL6 mice Benedikt Andreas Gasser1 & Johann Kurz2 & Walter Senn3 & Genevieve Escher1,4 & Markus Georg Mohaupt1,5 Received: 27 April 2020 /Accepted: 26 August 2020 # The Author(s) 2020 Abstract Various disturbances of social behavior, such as autism, depression, or posttraumatic stress disorder, have been associated with an altered steroid hormone homeostasis and a dysregulation of the hypothalamus–pituitary–adrenal axis. A link between steroid hormone antagonists and the treatment of stress-related conditions has been suggested. We evaluated the effects of stress induction on social behavior in the three chambers and its potential reversibility upon specific steroid hormone antagonism in mice. C57BL/6 mice were stressed twice daily for 8 days by chronic swim testing. Social behavior was evaluated by measuring, first, the preference for sociability and, second, the preference for social novelty in the three-chamber approach before and after the chronic swim test. The reversibility of behavior upon stress induction was analyzed after applying steroid hormone antag- onists targeting glucocorticoids with etomidate, mineralocorticoids with potassium canrenoate, and androgens with cyproterone acetate and metformin. In the chronic swim test, increased floating time from 0.8 ± 0.2 min up to 4.8 ± 0.25 min was detected (p < 0.01). In the three-chamber approach, increased preference for sociability and decreased preference for social novelty was detected pre- versus post-stress induction. These alterations of social behavior were barely affected by etomidate and potassium canrenoate, whereas the two androgen antagonists metformin and cyproterone acetate restored social behavior even beyond baseline conditions.
    [Show full text]
  • Aldactone® Spironolactone Tablets, USP
    NDA 12-151/S-062 Page 2 Aldactone® spironolactone tablets, USP WARNING Aldactone has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions). Aldactone should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. DESCRIPTION Aldactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula: Spironolactone is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, flavor, hypromellose, iron oxide, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide. ACTIONS / CLINICAL PHARMACOLOGY Mechanism of action: Aldactone (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Aldactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Aldactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone antagonist activity: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and the nephrotic syndrome. By competing with aldosterone for receptor sites, Aldactone provides effective therapy for the edema and ascites in those conditions.
    [Show full text]